Supernus Pharmaceuticals, Inc. (SUPN)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$42.76+0.90%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.5B
- Forward P/E
- 9.6
- 52-week range
- $40.51 – $59.68
- 52-week change
- −11.84%
- EPS (trailing)
- −$1.92
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $719M (+8.63%)
- Net income
- −$38.6M
- Operating margin
- −8.7%
- Diluted EPS
- −$0.68
- Free cash flow
- $46.0M
From the company’s annual report on SEC EDGAR.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea.
Headquarters: Rockville, United States · 778 employees · supernus.com